CTMX — CytomX Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1501989 ·
Last close
$2.57
Market Cap
$560.00M
52W High
$8.21
52W Low
$2.43
ADV30
3,933,815
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,418,000 | — | -23,781,000 | -20,666,000 | 381,226,000 | 17,224,000 | 79,158,000 |
| Mar 2026 | 10,258,000 | — | -19,672,000 | -18,248,000 | 359,358,000 | 28,828,000 | 39,414,000 |
| Dec 2025 | 663,000 | — | -27,932,000 | -26,510,000 | 151,566,000 | 12,667,000 | 52,558,000 |
| Sep 2025 | 5,963,000 | — | -15,768,000 | -14,229,000 | 158,254,000 | 34,185,000 | 50,865,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-82,408,000
Investing CF
$-200,804,000
Financing CF
$251,894,000
CapEx
$-427,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.28
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-750,863,000
Inventory
—
Receivables
$37,494,000
ST Investments
$313,056,000
EBIT TTM
$-87,153,000
Pretax Income TTM
$-79,422,000
Interest Exp TTM
—
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$18,303,000
EBITDA
$-86,211,000
Free Cash Flow
$-75,212,624
Enterprise Value
$392,312,640
Total Cash
$330,280,000
Total Debt
$5,704,000
Shares Out
217,899,284
Trailing EPS
$-0.57
Book Value
$1.39
ROE
-37.8%
ROA
-19.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 76,201,000 | -22,364,000 | -17,368,000 | 151,566,000 | 52,558,000 | 99,008,000 | -75,587,000 |
| Dec 2024 | 138,103,000 | 24,995,000 | 31,869,000 | 120,533,000 | 120,989,000 | -456,000 | -86,231,000 |
| Dec 2023 | 101,214,000 | -6,484,000 | -569,000 | 201,792,000 | 249,239,000 | -47,447,000 | -56,035,000 |
| Dec 2022 | 53,163,000 | -101,335,000 | -99,317,000 | 260,891,000 | 346,642,000 | -85,751,000 | -110,788,000 |
TTM Snapshot
Revenues TTM
$35,542,000
NetIncome TTM
$-59,141,000
OpCashFlow TTM
—
Assets (Latest)
$359,358,000
Forward EPS
$-0.47
Max Pain — expiry 2026-11-20
max pain strike: $4.00 · spot: $2.57 · call oi: 857 · put oi: 4,929
Expected Move to 2026-11-20:
±$1.23
(47.67%) —
implied range
$1.34 –
$3.79
· ATM straddle on $3.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ACRS | Aclaris Therapeutics, Inc. | $563.77M | $3.83 | — |
| BLSM | BlossomHill Therapeutics, Inc. | $555.60M | $17.48 | — |
| CBIO | CRESCENT BIOPHARMA, INC. | $553.82M | $14.91 | — |
| SGMT | Sagimet Biosciences Inc. | $550.01M | $8.93 | — |
| CRMD | CorMedix Inc. | $575.23M | $7.38 | — |
News headlines (Yahoo Finance, 1h cache)
CytomX Therapeutics to Present at Upcoming September Investor Conferences
2026-09-01 12:00 · Yahoo
CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlights: Varetta M Advances Toward ...
2026-08-07 05:03 · Yahoo
CytomX Therapeutics Q2 Earnings Call Highlights
2026-08-07 01:03 · Yahoo
CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates
2026-08-06 23:10 · Yahoo
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
2026-08-06 20:15 · Yahoo
CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer
2026-08-03 12:00 · Yahoo
CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
2026-07-30 12:00 · Yahoo
CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors
2026-07-27 12:00 · Yahoo
CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why
2026-07-08 16:00 · Yahoo
Is CytomX (CTMX) One of the Best Growth Stocks Under $30 to Buy Now?
2026-06-19 07:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.